Who Paid My Doc
Amitabh Goswami
Interventional Pain Medicine Fresno, CA Doctor of Osteopathy
NPI 1447451539 CMS profile 20013
7255 N. Cedar Ave, Suite 101, Fresno, CA 93720
General payments
$100,812
Research payments
$16
Ownership & investment interest
$655,789
Through program year 2025, Amitabh Goswami of Fresno, CA is reported in the CMS Open Payments database as having received $100,812 across 1,294 general payments and $16 in research payments paid to them. They also declared ownership or investment interests valued at $655,789 across 5 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $10,329 | 107 | |
| 2024 | General | $13,505 | 249 | |
| 2023 | General | $15,814 | 194 | |
| 2022 | General | $10,311 | 161 | |
| 2021 | General | $18,595 | 200 | |
| 2021 | Research | $16 | 1 | |
| 2020 | General | $12,051 | 135 | |
| 2019 | General | $20,207 | 248 | |
| 2025 | Ownership | $149,474 | 1 | |
| 2024 | Ownership | $149,474 | 1 | |
| 2023 | Ownership | $128,421 | 1 | |
| 2022 | Ownership | $128,421 | 1 | |
| 2021 | Ownership | $100,000 | 1 |
Beside peers
- Amitabh Goswami
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Amitabh Goswami were reported at $10,329. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Amitabh Goswami | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $20,207 | $684 | $216–$2,079 | $163 |
| 2020 | $12,051 | $382 | $122–$1,109 | $114 |
| 2021 | $18,595 | $552 | $167–$1,554 | $132 |
| 2022 | $10,311 | $605 | $187–$1,924 | $149 |
| 2023 | $15,814 | $671 | $195–$1,915 | $160 |
| 2024 | $13,505 | $684 | $206–$1,837 | $164 |
| 2025 | $10,329 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 25 drugsPart D claims
1,461
Drug cost
$76,017
Branded share of claims
29.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Nucynta Tapentadol Hcl | Brand | 13 | $24,687 | |
| Horizant Gabapentin Enacarbil | Brand | 21 | $15,018 | |
| Belbuca Buprenorphine Hcl | Brand | 12 | $11,840 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 320 | $4,520 | |
| Ztlido Lidocaine | Brand | 12 | $4,375 | |
| Lidocaine | Generic | 70 | $3,987 | |
| Gabapentin | Generic | 468 | $3,651 | |
| Duloxetine Hcl | Generic | 131 | $1,729 | |
| Clonidine | Generic | 14 | $1,290 | |
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 20 | $1,167 |
The 10 drugs with the highest cost, of 25 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 142 billing codesPaid by Medicare
$1,111,815
Medicare patients
964
Services billed
31,112
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 38% | |
| Diabetes | 33% | |
| Depression | 29% | |
| Chronic kidney disease | 25% | |
| Osteoporosis | 24% | |
| Heart failure | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 13 | 4,700 | $22,030 |
| Injection, pyridoxine hcl, 100 mg J3415 | Office | 63 | 929 | $10,178 |
| Injection, thiamine hcl, 100 mg J3411 | Office | 63 | 933 | $1,514 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 376 | 1,599 | $1,210 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 | Office | 70 | 998 | $1,011 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 60 | 792 | $785 |
| Injection, magnesium sulfate, per 500 mg J3475 | Office | 63 | 944 | $418 |
| 5% dextrose/normal saline (500 ml = 1 unit) J7042 | Office | 32 | 266 | $243 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 49 | 131 | $71 |
| Ringers lactate infusion, up to 1000 cc J7120 | Office | 20 | 32 | $61 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| HORIZANT |
|
$25 | 21 | — |
| BOTOX |
|
$21 | — | 4,700 |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
1,295 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in California
Michael Verdolin
Interventional Pain Medicine · La Mesa, CA
Tim Leier
Interventional Pain Medicine · Rancho Mirage, CA
Jonathan Grossman
Interventional Pain Medicine · Visalia, CA
Kasra Maasumi
Interventional Pain Medicine · Rancho Santa Margarita, CA
Andrew Germanovich
Interventional Pain Medicine · Rancho Mirage, CA
David Lee
Interventional Pain Medicine · Yorba Linda, CA
Related records
Interventional Pain Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.